Literature DB >> 19092831

Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells.

Syamal K Datta1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19092831      PMCID： PMC2713746          DOI： 10.1038/ncprheum0983

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN： 1745-8382


× No keyword cloud information.
  21 in total

Review 1.  B-cell targeting in rheumatoid arthritis and other autoimmune diseases.

Authors:  Jonathan C W Edwards; Geraldine Cambridge
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

2.  ITP three R's: regulation, routing, rituximab.

Authors:  John W Semple
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

3.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

4.  Antigen-specific interaction between T and B cells.

Authors:  A Lanzavecchia
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

5.  T cell activation in rheumatoid synovium is B cell dependent.

Authors:  S Takemura; P A Klimiuk; A Braun; J J Goronzy; C M Weyand
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

6.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Authors:  Anne H Cross; Jennifer L Stark; Joanne Lauber; Michael J Ramsbottom; Jeri-Anne Lyons
Journal:  J Neuroimmunol       Date:  2006-08-14       Impact factor: 3.478

7.  Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets.

Authors:  Hee-Kap Kang; Marissa A Michaels; Beate R Berner; Syamal K Datta
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

Review 8.  Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

Authors:  Stamatis-Nick C Liossis; Petros P Sfikakis
Journal:  Clin Immunol       Date:  2008-03-11       Impact factor: 3.969

9.  The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Authors:  Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

10.  Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors.

Authors:  K L Rock; B Benacerraf; A K Abbas
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307
View more
  10 in total

Review 1.  Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.

Authors:  Kazunari Kaneko; Shoji Tsuji; Takahisa Kimata; Tetsuya Kitao; Sohsaku Yamanouchi; Shogo Kato
Journal:  World J Pediatr       Date:  2015-01-28       Impact factor: 2.764

2.  Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.

Authors:  Andreas Kronbichler; Paul König; Martin Busch; Gunter Wolf; Gert Mayer; Michael Rudnicki
Journal:  Wien Klin Wochenschr       Date:  2013-04-27       Impact factor: 1.704

3.  Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates.

Authors:  Antonio Fontanellas; Sandra Hervás-Stubbs; Itsaso Mauleón; Juan Dubrot; Uxua Mancheño; María Collantes; Ana Sampedro; Carmen Unzu; Carlos Alfaro; Asis Palazón; Cristian Smerdou; Alberto Benito; Jesús Prieto; Iván Peñuelas; Ignacio Melero
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

4.  Marginal zone precursor B cells as cellular agents for type I IFN-promoted antigen transport in autoimmunity.

Authors:  John H Wang; Jun Li; Qi Wu; PingAr Yang; Rahul D Pawar; Shutao Xie; Laura Timares; Chander Raman; David D Chaplin; Lu Lu; John D Mountz; Hui-Chen Hsu
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

5.  Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.

Authors:  A Alunno; F Carubbi; O Bistoni; S Caterbi; E Bartoloni; P Di Benedetto; P Cipriani; R Giacomelli; R Gerli
Journal:  Clin Exp Immunol       Date:  2016-03-03       Impact factor: 4.330

6.  Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?

Authors:  Andreas Kronbichler; Gert Mayer
Journal:  J Nephropathol       Date:  2014-01-01

7.  A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.

Authors:  Marinus J Dekkers; Jaap W Groothoff; Robert Zietse; Michiel G H Betjes
Journal:  BMC Res Notes       Date:  2015-06-26

8.  Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.

Authors:  Roberta Fenoglio; Savino Sciascia; Giulietta Beltrame; Paola Mesiano; Michela Ferro; Giacomo Quattrocchio; Elisa Menegatti; Dario Roccatello
Journal:  Oncotarget       Date:  2018-06-22

Review 9.  Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association.

Authors:  Manuel Alfredo Podestà; Claudio Ponticelli
Journal:  Front Med (Lausanne)       Date:  2020-11-20

10.  Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.

Authors:  Maximilian Webendörfer; Linda Reinhard; Rolf A K Stahl; Thorsten Wiech; Hans-Willi Mittrücker; Sigrid Harendza; Elion Hoxha
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.